



SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093
Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, CIN : L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2016

S. No.	Particulars (Rs. in lacs)	Quarter Ended			Half Year Ended		Year Ended
		30.09.2016 (Unaudited)	30.06.2016 (Unaudited)	30.09.2015 (Unaudited)	30.09.2016 (Unaudited)	30.09.2015 (Unaudited)	31.03.2016 (Audited)
01	(a) Net Income From Operations	4676.69	4282.61	4977.70	8959.30	8910.16	18190.48
	(b) Other Operating Income	41.83	66.77	33.95	108.60	105.26	199.22
	Total Income from Operation	4718.52	4349.38	5011.65	9067.90	9015.42	18389.70
02	Expenses						
	(a) Cost of Materials consumed	1669.17	1660.95	2310.11	3330.12	4447.17	6890.03
	(b) Purchase of stock in trade	1879.09	848.04	1042.72	2727.13	1814.30	6630.17
	(c) Changes in inventories	(190.51)	482.73	216.29	292.22	62.50	(365.04)
	(d) Employee benefits expenses	301.09	360.45	315.25	661.54	650.26	1361.37
	(e) Depreciation and amortization expenses	85.00	85.00	86.00	170.00	171.00	299.81
	(f) Other expenses	622.18	612.44	585.90	1234.62	1155.86	2212.82
	Total Expenses	4366.02	4049.61	4556.27	8415.63	8301.09	17029.16
03	Profit/(Loss) from Operations before other (1-2) income, finance costs and exceptional items	352.50	299.77	455.38	652.27	714.33	1360.54
04	Other Income	86.67	85.12	41.80	171.79	66.44	266.83
05	Profit/(Loss) from Ordinary activities before finance costs and exceptional items (3+4)	439.17	384.89	497.18	824.06	780.77	1627.37
06	Interest & Financial Charges	6.77	6.90	1.05	13.67	3.10	7.09
07	Operating Profit after interest & exceptional items(5-6)	432.40	377.99	496.13	810.39	777.67	1620.28
08	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
09	Profit/(Loss) from Ordinary activities before tax	432.40	377.99	496.13	810.39	777.67	1620.28
10	Tax expenses	135.00	125.00	175.80	260.00	232.30	574.53
11	Net Profit(+)/Loss(-) from ordinary activities after tax(9-10)	297.40	252.99	320.33	550.39	545.37	1045.75
12	Extraordinary items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	10.19
13	Net Profit(+)/Loss(-) for the period (11+12)	297.40	252.99	320.33	550.39	545.37	1035.56
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority interest	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit/(Loss) after taxes, minority interest & share of profit/loss of associates (13+14+15)	297.40	252.99	320.33	550.39	545.37	1035.56
17	Paid-up equity Share Capital (Equity share of Rs. 1 each)	7806.52	7806.52	7806.52	7806.52	7806.52	7806.52
18	Reserves (excluding Revaluation Reserves)	0.00	0.00	0.00	0.00	0.00	3063.44
19	(I) Earning Per Share (EPS) before extraordinary items (in 1/- each) (not annualised)						
	a) Basic Earning per share	0.04	0.03	0.04	0.07	0.06	0.13
	b) Diluted Earning Per Share	0.04	0.03	0.04	0.07	0.06	0.13
19	(II) Earning Per Share (EPS) (after extraordinary items (in 1/- each) (not annualised)						
	a) Basic Earning per share	0.06	0.03	0.04	0.07	0.06	0.13
	b) Diluted Earning Per Share	0.06	0.03	0.04	0.07	0.06	0.13

SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS

S. No.	Particulars (Rs. in lacs)	Quarter Ended			Half Year Ended		Year Ended
		30.09.2016 (Unaudited)	30.06.2016 (Unaudited)	30.09.2015 (Unaudited)	30.09.2016 (Unaudited)	30.09.2015 (Unaudited)	31.03.2016 (Audited)
1	Segment Revenue						
	(a) Pharmaceuticals Drugs & Formulations	3893.38	4011.91	3484.98	7905.29	7413.35	16862.50
	(b) Trading of Commodities	836.42	356.01	1548.71	1192.43	1637.88	1713.42
	(c) Renting of Property	75.40	66.58	19.75	141.98	30.63	80.61
	Total	4805.20	4434.50	5053.44	9239.70	9081.86	18656.53
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Net Sales/Income from Operations	4805.20	4434.50	5053.44	9239.70	9081.86	18656.53
2	Segment Results (Profit)+/Loss(-) before tax and interest from each Segment						
	(a) Pharmaceuticals Drugs & Formulations	238.50	312.97	402.08	551.49	677.34	1463.91
	(b) Trading of Commodities	125.25	5.35	64.48	130.60	72.80	82.84
	(c) Renting of Property	75.40	66.58	30.63	141.98	30.63	80.61
	Total	439.15	384.90	497.18	824.05	780.77	1627.36
	Less: (i) Interest	6.77	6.90	1.04	13.67	3.10	7.09
	(ii) Other Un-allocable Expenditure net off	0.00	0.00	0.00	0.00	0.00	0.00
	(iii) Un-allocable Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Profit Before Tax	432.40	378.00	496.14	810.38	777.67	1620.28
3	Capital Employed						
	(Segment Assets - Segment Liabilities)						
	(a) Pharmaceuticals Drugs & Formulations	8025.80	7641.58	9822.60	8025.80	9822.60	8692.60
	(b) Trading of Commodities	231.40	329.97	1.34	231.40	1.34	113.29
	(c) Renting of Property	3943.84	3907.12	991.84	3943.84	991.84	2690.78
	(d) Unallocated	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed	12201.04	11878.66	10815.77	12201.04	10815.77	11496.66



SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093
Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, CIN : L24239MH1988PLC047759

STATEMENT OF ASSETS & LIABILITY AS AT 30/09/2016

Particulars (Rs. in lacs)		AS AT 30.09.2016 (Unaudited)	AS AT 31.03.2016 (Audited)
A. EQUITY AND LIABILITIES			
Shares holders' fund			
(a) Share capital		7806.52	7806.52
(b) Reserve and surplus		3613.82	3063.44
(c) Money received against share warrants		0.00	0.00
Sub total - shareholders' funds		11420.34	10869.96
Share application money pending allotment		0.00	0.00
Minority interest		0.00	0.00
Non-current liabilities			
(a) Long-term borrowing		0.00	0.00
(b) Deferred tax liabilities (net)		609.57	584.57
(c) Long-term liabilities		171.13	42.13
(d) Long-term provisions		0.00	0.00
Sub total - noncurrent liabilities		780.70	626.70
Current liabilities			
(a) Short-term borrowing		1292.77	562.20
(b) Trade payables		2804.96	4693.62
(c) Other current liabilities		84.42	366.79
(d) Short-term provisions		409.12	420.90
Sub total - noncurrent liabilities		4591.27	6043.51
TOTAL - EQUITY AND LIABILITIES		16792.31	17540.17
B. ASSETS			
Non-current assets			
(a) Fixed assets		4211.81	5056.86
(b) Goodwill on consolidation		0.00	0.00
(c) Non-current investments		4539.60	2347.43
(d) Deferred tax assets (net)		0.00	0.00
(e) Long-term loans and advances		523.83	1505.42
(f) Other non-current assets		0.00	0.00
Sub total - noncurrent assets		9275.24	8909.71
Current assets			
(a) Current investments		0.00	0.00
(b) Inventories		1166.77	1546.81
(c) Trade receivables		3602.81	4599.69
(d) Cash and cash equivalents		574.80	569.41
(e) Short-term loans and advances		2104.36	1869.87
(f) Other current assets		68.33	44.68
Sub total - current assets		7517.07	8630.46
TOTAL ASSETS		16792.31	17540.17

Notes :

- The above Unaudited Financial Results were reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meetings held on 14th November 2016.
- The limited review under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The report does not contain anything which would have an impact on the results for the Quarter ended 30th September 2016.
- The company is operating in three segment i.e.: (a.)Pharmaceutical Drugs & Formulations. (b.)Trading of commodities (c) Renting of Property.
- Figures for the previous periods/year have been regrouped wherever necessary.

Place : Indore
Dated : 14/11/2016

By order of The Board of Directors
For Syncom Formulations (India) Ltd.

Kedarmal Bankda
Chairman & Wholetime Director